The 44th Annual J.P. Morgan Healthcare Conference will take place January 12–15 in San Francisco, USA.

Dr. Anjin Xianyu, CTO of META, and Dr. Zhen Cao, Executive Director of Business Development and Translational Medicine, will attend the conference together to present our lead asset, MP-5342 — the world’s first oral small molecule inhibitor of lactate dehydrogenase (LDH) originating from a novel biological theory.

As one of the most influential annual gatherings in global healthcare, the JPM Conference is widely regarded as a key window for global capital markets to observe biopharma innovation and industry trends. This year’s event is expected to bring together over 8,000 attendees in San Francisco to discuss frontier trends and collaboration opportunities.

META looks forward to engaging with industry partners at the conference to jointly advance innovation in healthcare.